Today, the European Parliament formally endorsed the deal on the revision of the European Pharmaceutical legislation. This compromise is the result of intense and lengthy debate, which aimed to improve the access, availability, and affordability of medicines and to prevent further delays of this much needed reform.
For the last three decades, the availability of cost-effective generic medicines has driven increased access to life-saving treatments for millions of patients in Europe. Today, these medicines are an integral part of the healthcare system.
Medicines for Europe members supply most of the essential prescription medicines in Europe, accounting for 67% of dispensed medicines. These medicines cover 80% of therapy areas, including for major and debilitating diseases such as cardiovascular disease, auto-immune conditions, cancer, and diabetes, among many others.
The upcoming European elections will have a significant impact on the future of health policy in Europe. EU policies and decisions can shape national health systems and influence the health and well-being of millions of citizens across Europe.
Biosimilar medicines were invented in Europe over 15 years ago. Since then, they have increased patient access to essential biologic medicines needed to treat the most serious of diseases like cancer, autoimmune conditions and diabetes by well over 50%.
Today, the Members of the Parliament’s health committee (ENVI) adopted a compromise position on the EU Pharmaceutical legislation review (comprising of a new Pharmaceutical Directive and Regulation). The Parliament has prioritised advancing this important legislation to improve the access, availability, and affordability of medicines ahead of the EU elections in June 2024 and prevent further delays of this much needed reform.
The position adopted today by the European Parliament on the proposals for the Unitary Supplementary Protection Certificate (SPC) and SPC Regulation recast, led by MEP Tiemo Wolken, is a significant milestone for innovation and access to medicines across Europe in this important legislative process.
Medicines for Europe’s newly published position paper explores how the current design of procurement rules in EU Member States, often aimed exclusively at reducing costs, has led to the consolidation of supply and increased risks for supply security.
Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.
Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.